McKesson raised its fiscal 2027 adjusted earnings outlook after reporting first-quarter revenue of $105.4 billion, up 8%, and adjusted diluted earnings per share of $9.93, up 20%. The company now expects full-year adjusted EPS of $44.20 to $45.00, up from prior guidance of $43.80 to $44.60, implying growth of 13% to 15%. North American Pharmaceutical revenue rose 5% to $86.8 billion, with operating profit up 19% to $894 million, while GLP-1 distribution revenue surged 24% to $15 billion. Oncology & Multispecialty and Prescription Technology Solutions both posted double-digit operating-profit growth. McKesson also advanced the planned separation of its Medical-Surgical Solutions business under the Wellverse brand and returned $2.6 billion to shareholders through buybacks and dividends, including a 15% dividend increase.
McKesson CorporationRaised fiscal 2027 EPS guidance and reported strong Q1 earnings with 20% EPS growth.
